
NanoString Blog

Oncology
miRNA Profiling in Malignant Melanoma: Making “Australia’s National Cancer” Obsolete.
Australia is a sun-worshipping country, the world capital for beautiful beaches, athletic surfers, cute marsupials, and the occasional weird-looking animal. But it is also the capital for something less pleasant:…

Neuroscience
A Systematic Evaluation of Immune Response and Plaque Microenvironment Variation in Alzheimer’s Disease
Alzheimer’s disease (AD) – the most prevalent form of dementia – is associated with defining histopathological features that include amyloid-beta (Aβ) plaque deposition and tau protein aggregation, accompanied by synaptic…

Oncology
Mapping the miRNA-mRNA Interactome in Multiple System Atrophy
A rapidly developing and fatal neurodegenerative disorder, MSA is frequently misdiagnosed or undetected until later stages due to its systemic nature, undefined etiopathogenesis, and multifaceted clinical presentation. In an attempt…

Oncology
Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Dr. Lisa Butterfield, PhD recently joined the Parker Institute for Cancer Immunotherapy as Vice President focusing on cell therapies while she continues her independent cancer vaccine research as an Adjunct…

Autoimmunity
Identifying Signaling Pathways and Biomarkers in Autoimmune Diseases
As efforts in developing targeted therapies for autoimmune disease are rapidly advancing in basic research, scientists aim to validate immunology-relevant signaling pathways and uncover new intracellular molecules as potential drug…

Neuroscience
New Biology-Driven Drug Discoveries Needed for Treating of Alzheimer’s
Alzheimer’s disease (AD) is a slowly progressing neurodegenerative disorder that affects millions of people worldwide, leaving behind an immense psychological, emotional, and financial burden on patients, caregivers, and healthcare systems.…

Autoimmunity Immunology
Q&A with Dr. Oliver Brain: Unintended Consequences Create a Unique Opportunity to Study Inflammatory Bowel Disease.
Oliver Brain, MRCP, PhD, is a principal investigator at the University of Oxford, Nuffield Department of Clinical Medicine, and a recent winner of an nCounter® Autoimmune Profiling Panel through a…

Autoimmunity
Q&A with Dr. Salla Keskitalo: Challenges and Opportunities in Studying Rare and Ultra-rare Autoimmune Diseases
Dr. Salla Keskitalo is a Senior Research Scientist at the University of Helsinki and a recent winner of NanoString’s Autoimmunity Grant Program. She made time to speak with us about…

Oncology
Q&A with Drs. Torsten Nielsen and Tony Ng and Angela Goytain: Development of a Sarcoma Gene Fusion Assay Faster Than FISH and Simpler than NGS
The NanoString nCounter is Research Use Only and not for diagnostic use. The views expressed herein are solely those of the interviewed researchers. Torsten Nielsen, MD, PhD is a pathologist…

Neuroscience
Q&A with Dr. Gregory Carter: Developing Computational Strategies and the MODEL-AD Consortium
Gregory Carter, Ph.D., is an Associate Professor at The Jackson Laboratory. His work is focused on developing computational strategies using genetic data to understand complex genetic systems. We recently spoke…

Neuroscience
Meta-analysis of AMP-AD Datasets Defines the Transcriptional Landscape of Alzheimer’s Disease
The Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) Consortium was formed to accelerate the development of diagnostics and therapeutics for this devastating and complex disease. One roadblock to development is…

Miscellaneous
NanoString-based publications 2018: A year in review
2018 was an incredibly productive year for scientific publications showcasing the NanoString platform and assays. We added nearly 500 publications of various scientific disciplines which are available on our website here.…